Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORE LABORATORIES N VCLB · Entity 11862 | Director | April 01, 2023 | April 03, 2023 |
| Core Laboratories Inc. /DE/CLB · Entity 5382 | Director | April 01, 2025 | April 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORE LABORATORIES N V
Report date April 01, 2023 · Filed April 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 16,467 |
Reported balance
After 2023-04-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-04-01 · Tax withholding · Disposed 2,524 · Balance 16,467 |
| Common SharesSEC Table I · non-derivative | Direct | 18,991 |
Reported balance
After 2023-04-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-04-01 · Exercise / conversion · Acquired 5,485 · Balance 18,991 |
| Restricted SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,419 |
Reported balance
After 2023-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-01 · Grant · Acquired 6,419 · Balance 6,419 F1: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2024, subject to the terms of issuance. |
| Restricted SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2023-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-01 · Exercise / conversion · Disposed 5,485 · Balance 0 F2: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2024, subject to the terms of issuance.
F2: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2023.
Core Laboratories Inc. /DE/
Report date April 01, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,552 |
Reported balance
After 2025-04-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-04-01 · Tax withholding · Disposed 4,634 · Balance 24,552 |
| Common StockSEC Table I · non-derivative | Direct | 29,186 |
Reported balance
After 2025-04-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-04-01 · Exercise / conversion · Acquired 9,317 · Balance 29,186 |
| Restricted SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-01 · Exercise / conversion · Disposed 9,317 · Balance 0 F1: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 2, 2025 14:33 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 9,317 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049157 · ownership.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025. F1 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 14:33 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 9,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049157 · ownership.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 14:33 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 4,634 | $14.98 | $69,417.32 |
DisclosureSEC source: 0000950170-25-049157 · ownership.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,552 Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 17:10 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 6,419 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040347 · ownership.xml · derivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2024. F2 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2024. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 17:10 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantRestricted Shares · Derivative | 9,317 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040347 · ownership.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,317 Underlying: Common Stock · 9,317 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2025, subject to the terms of issuance. F1 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2025, subject to the terms of issuance. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 17:10 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 6,419 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040347 · ownership.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 17:10 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 3,017 | $17.13 | $51,681.21 |
DisclosureSEC source: 0000950170-24-040347 · ownership.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,869 Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 13:41 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 5,485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022054 · doc4.xml · derivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,485 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2023. F2 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 13:41 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 6,419 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022054 · doc4.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,419 Underlying: Common Shares · 6,419 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2024, subject to the terms of issuance. F1 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2024, subject to the terms of issuance. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 13:41 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 5,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022054 · doc4.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 13:41 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 2,524 | $22.05 | $55,654.20 |
DisclosureSEC source: 0001209191-23-022054 · doc4.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,467 Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 4,307 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022513 · doc4.xml · derivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period on April 1, 2022. F2 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 5,485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022513 · doc4.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,485 Underlying: Common Shares · 5,485 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2023, subject to the terms of issuance. F1 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2023, subject to the terms of issuance. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 4,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022513 · doc4.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 1,982 | $32.43 | $64,276.26 |
DisclosureSEC source: 0001209191-22-022513 · doc4.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,506 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 4,307 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025322 · doc4.xml · derivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307 Underlying: Common Shares · 4,307 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2022, subject to the terms of issuance. F2 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2022, subject to the terms of issuance. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 14,507 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025322 · doc4.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2021. F1 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 6,746 | $30.10 | $203,054.60 |
DisclosureSEC source: 0001209191-21-025322 · doc4.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,181 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 14,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025322 · doc4.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 14,507 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022449 · doc4.xml · derivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,507 Underlying: Common Shares · 14,507 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2021, subject to the terms of issuance. F2 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2021, subject to the terms of issuance. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 2,177 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022449 · doc4.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,177 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2020. F1 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2020. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 1,013 | $9.49 | $9,613.37 |
DisclosureSEC source: 0001209191-20-022449 · doc4.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,420 Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 2,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022449 · doc4.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 2,177 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · derivative · entry 7 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,177 Underlying: Common Shares · 2,177 shares Expires not disclosed F3 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2020, subject to the terms of issuance. F3 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2020, subject to the terms of issuance. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 1,387 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · derivative · entry 6 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2019. F2 · derivative.expiration_date: The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 1,335 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · derivative · entry 5 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vested at the end of a three-year vesting period ending April 1, 2019. F1 · derivative.expiration_date: The Restricted Shares vested at the end of a three-year vesting period ending April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 645 | $68.93 | $44,459.85 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · nonDerivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,256 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 1,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · nonDerivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 621 | $68.93 | $42,805.53 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 1,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000042 · wf-form4_155423518661033.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 17:27 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 1,299 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000055 · wf-form4_152279080062379.xml · derivative · entry 4 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Shares vested, without performance criteria, at the end of a one-year vesting period ending April 1, 2018, subject to the terms of issuance. F2 · derivative.expiration_date: The Restricted Shares vested, without performance criteria, at the end of a one-year vesting period ending April 1, 2018, subject to the terms of issuance. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 17:27 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 1,387 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000055 · wf-form4_152279080062379.xml · derivative · entry 3 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387 Underlying: Common Shares · 1,387 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2019, subject to the terms of issuance. F1 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2019, subject to the terms of issuance. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 17:27 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 605 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000055 · wf-form4_152279080062379.xml · nonDerivative · entry 2 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 17:27 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 1,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000055 · wf-form4_152279080062379.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 16:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Shares · Derivative | 1,299 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000053 · wf-form4_149133952013138.xml · derivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299 Underlying: Common Shares · 1,299 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2018, subject to the terms of issuance. F1 · derivative.expiration_date: The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period ending April 1, 2018, subject to the terms of issuance. Read SEC document |
| February 01, 2017 Filed Feb 1, 2017 17:01 UTC | CORE LABORATORIES N V CLB · Entity 11862 | PurchaseCommon Shares | 106 | $118.65 | $12,576.90 |
DisclosureSEC source: 0001000229-17-000022 · wf-form4_148598650233032.xml · nonDerivative · entry 1 Straughen Michael · CIK 0001677384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.